LSD Trial Success Paves Way for US Anxiety Approval by 2027
Definium Therapeutics reports its investigational LSD tablet met primary endpoints in a phase III trial, potentially leading to regulatory approval in the United States within two years.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 2 articles since 15 Sept 2026. New Scientist published first, on 15 September at 12:00 UTC; MedPageToday.com - medical news for physicians followed 31h 39m later. The most recent article, from MedPageToday.com - medical news for physicians, appeared on 16 September at 19:38 UTC.
Outlets reporting it: New Scientist, MedPageToday.com - medical news for physicians.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Definium Therapeutics
- Contineum Therapeutics
- LSD
- United States